Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms 1Burkitt Lymphoma 1Agnosia 1

Interventions

Cisplatin 14Carboplatin 12Magnetic Resonance Spectroscopy 11Specimen Handling 10Gemcitabine 10pembrolizumab 8Pemetrexed 8atezolizumab 7Paclitaxel 7Radiotherapy, Intensity-Modulated 5Platinum 5Nivolumab 5Immunoglobulin G 5Doxorubicin 5Docetaxel 5Disulfides 5Bevacizumab 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5Cetuximab 4Biopsy 4durvalumab 3Temozolomide 3Standard of Care 3Rituximab 3Drug Therapy 3Dexamethasone 3Cyclophosphamide 3(225)Ac-DOTA-c(RGDyK) 3venetoclax 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Acetaminophen × 30 days × Clear all
NCT07570173 2026-06-05

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT05597878 2026-06-01

Opioid-Free Pain Control Regimen Following Robotic Radical Prostatectomy

Wake Forest University Health Sciences

Phase 2/3 Terminated
58 enrolled
Genitourinary

Agnosia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡